Roquefort Therapeutics (LON:COIL) Stock Jumps 0.5% – Here’s What Happened

Posted by Francis Steltz on Oct 12th, 2026

Roquefort Therapeutics plc (LON:COIL – Get Free Report)’s share price was up 0.5% during trading on Monday. The company traded as high as GBX 6.85 and last traded at GBX 6.25. 6,342,298 shares traded hands during trading, an increase of 2,314% from the average daily volume of 262,781 shares. The stock had previously closed at GBX 6.22.

Analyst Upgrades and Downgrades

Separately, Shore Capital Group reissued a “house stock” rating on shares of Roquefort Therapeutics in a research report on Monday, September 21st.

View Our Latest Analysis on Roquefort Therapeutics

Roquefort Therapeutics Trading Up 0.5%

The business has a 50 day moving average of GBX 8.39 and a two-hundred day moving average of GBX 9.11. The company has a current ratio of 0.63, a quick ratio of 3.07 and a debt-to-equity ratio of 8.18. The firm has a market cap of £26.67 million, a P/E ratio of -0.31 and a beta of 0.05.

Roquefort Therapeutics (LON:COIL – Get Free Report) last released its quarterly earnings data on Monday, September 28th. The company reported GBX (1.66) EPS for the quarter. Roquefort Therapeutics had a negative return on equity of 18.71% and a negative net margin of 57,057.07%.

Insider Buying and Selling at Roquefort Therapeutics

In related news, insider Stephen Paul West acquired 270,306 shares of the company’s stock in a transaction dated Monday, September 28th. The shares were bought at an average cost of GBX 7 per share, with a total value of £18,921.42. 36.27% of the stock is owned by insiders.

About Roquefort Therapeutics

(Get Free Report)

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.